semaglutide · brazil

Semaglutide in Brazil

Wegovy was ANVISA-approved January 2023 — Brazil was one of the first ex-US Wegovy markets. Ozempic established earlier. Premium private hospital chains anchor the trustworthy route; ANVISA's retained-prescription enforcement makes the hospital channel mandatory for trust.

Legal status

ANVISA-registered for Wegovy (Jan 2023), Ozempic (earlier), and Rybelsus. Brazil was one of the first ex-US Wegovy markets. Prescription-only with retained-prescription mandate. Off-label Ozempic-for-weight prescribing legal and common.

Monthly price bands

What it actually costs.

Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.

Albert Einstein / Sírio-Libanês premium Wegovy

Per month including endo consult + bloodwork. Wegovy R$1,065+/box; Mounjaro R$4,058+/box at premium tier.

$420 to $700
/ month
Off-label Ozempic at private hospital

Per month. Cheaper than Wegovy, equally effective at maintenance dose. Hospital prescription required.

$280 to $440
/ month
ANVISA-channel pharmacy retail

Per month at typical maintenance dose. Drogasil / Drogaria São Paulo / Pague Menos. Hospital prescription required.

$220 to $380
/ month
Legal routes

How to get it — on the right side of the line.

Route 1

Hospital Israelita Albert Einstein

JCI since 1999, Newsweek World #16 / #1 Brazil. Centro de Prevenção e Tratamento da Obesidade. Named obesity endocrinologists Dr Paulo Rosenbaum and Dr Clayton Macedo (SBEM director) on public record discussing Wegovy/Mounjaro protocols.

Route 2

Hospital Sírio-Libanês

JCI 2007 + JCI Primary Care 2024. Obesidade e Cirurgia Bariátrica center + dedicated Centro de Diabetes. Named coordinator Dra. Claudia Cozer Kalil (Obesity & Eating Disorders Center).

Route 3

Off-label Ozempic via hospital + retail pharmacy

Cheaper alternative to Wegovy. ANVISA-channel pharmacy fulfillment with hospital prescription. The cheapest legitimate route for Brazilian-resident patients.

Availability by channel

What channels actually work here.

Clinic (brand)
Available

Wegovy + Ozempic widely available at premium hospitals; ANVISA channel mature.

Compounding pharmacy
Not routed

Compounded semaglutide is ANVISA-contested grey market; Panya does not route there.

Research-chem direct
Not routed

ANVISA enforcement active.

Telehealth
Available

Einstein + Sírio-Libanês both run telehealth + in-person hybrid.

In practice

Brazil is the most-mature LatAm GLP-1 market. Wegovy launched here ahead of most other ex-US countries. For Brazilian-resident patients with private insurance, Einstein or Sírio-Libanês is the default trustworthy lane. For cross-border arbitrage seekers, India and Bangkok undercut on price.

Current supply

What's actually in stock right now.

Per-brand stock state for semaglutide in this region, sourced from cohort research and operator feedback. Each entry has a verifiedAt date so you can judge freshness. Confirm at the specific provider before booking.

Wegovy
Stable

ANVISA-approved Jan 2023 — Brazil was one of the first ex-US Wegovy markets. Premium hospital channel mature.

0d ago
Ozempic
Stable

Established T2D + off-label weight. Cheaper than Wegovy. Drogasil / Pague Menos retail.

0d ago
The other molecule

Tirzepatide in Brazil

Mounjaro / Zepbound — dual GLP-1 + GIP agonist. Eli Lilly. Stronger weight effect head-to-head than semaglutide; also more expensive and supply has been more constrained globally.

Ready

Match me to a vendor in Brazil.

Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.

We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.